Biomarkers to predict the clinical efficacy of bevacizumab in cancer. [electronic resource]
Producer: 20110112Description: 1172-83 p. digitalISSN:- 1474-5488
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Biomarkers, Tumor -- blood
- Clinical Trials, Phase III as Topic
- Humans
- Neoplasms -- drug therapy
- Polymorphism, Genetic
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.